Funding for this research was provided by:
canadian institutes of health research (381280)
genome canada (OGI-150)
Received: 22 October 2021
Accepted: 27 March 2022
First Online: 11 April 2022
: Ethics approval for the following research was granted by the Conjoint Health Research Ethics Board at the University of Calgary (REB 19–0471).
: Not applicable.
: DAM reports non-financial support from consultancy (Illumina) and ISPOR, and personal fees from Analytica, outside the submitted work. RSMY reports consulting fees from Novartis and Lily outside the submitted work. SV reports grants and personal fees from SOBI and Novartis during the conduct of the study. JS reports grants from SOBI, outside the submitted work. All other authors declare that they have no competing interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.